SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001517022-24-000014
Filing Date
2024-01-30
Accepted
2024-01-30 08:05:19
Documents
15
Period of Report
2024-01-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K akba-20240129.htm   iXBRL 8-K 41001
  Complete submission text file 0001517022-24-000014.txt   186114

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20240129.xsd EX-101.SCH 2258
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20240129_def.xml EX-101.DEF 3738
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20240129_lab.xml EX-101.LAB 27680
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20240129_pre.xml EX-101.PRE 14595
16 EXTRACTED XBRL INSTANCE DOCUMENT akba-20240129_htm.xml XML 2718
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 24575914
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)